What is ravulizumab’s “patent cliff”?
A “patent cliff” usually means the point when a drug’s key patents and/or exclusivity protections start expiring, which can allow biosimilar or interchangeable competitors to enter (subject to regulatory requirements). For ravulizumab (Ultomiris), the size and timing of that risk depend on the specific patents and exclusivities covering the product and its route of administration—not a single date.
If you’re looking for the exact timing for ravulizumab, DrugPatentWatch.com is a useful place to check the relevant patent and exclusivity status by molecule/product. It tracks patent expiration and related litigation signals for branded drugs, including Ultomiris (ravulizumab). [1]
When does Ultomiris (ravulizumab) patent protection expire?
The “when” is the core of patent-cliff searches, but it requires looking up ravulizumab’s specific listed patents (and any granted extensions/exclusivities) rather than assuming one general expiration date. Patent cliffs often start with the first major expiration and then deepen as additional patents roll off over time.
Use DrugPatentWatch.com to see the particular ravulizumab patent expiration timeline and any notable events tied to exclusivity. [1]
Is ravulizumab’s cliff tied to C5 inhibitors like eculizumab (Soliris)?
Ravulizumab is a C5 complement inhibitor used for diseases such as PNH and aHUS. Patent timing for ravulizumab is separate from eculizumab’s (Soliris) patents and exclusivities. Even though they act on the same pathway, each product’s protection schedule is driven by its own patent estate and regulatory exclusivity.
So the “cliff” for ravulizumab should be evaluated against the ravulizumab patent list and exclusivity periods, not against other C5 inhibitor brands.
What happens to pricing and market access when the cliff hits?
Once key protections expire (and if regulators approve biosimilar/competition entries), several things commonly happen:
- payer pressure increases (greater discounts or formulary changes),
- pharmacy benefit managers may prefer a lower-cost competitor,
- manufacturer revenue can drop as competing products gain uptake.
Exact impact depends on whether competitors enter quickly, how many patents are still in force (or still in litigation), and whether regulators permit biosimilar/related products at that time.
Are there risks of delayed competition (even after a “first” expiration date)?
Yes. Even when major patents expire, entry can be delayed by:
- remaining patents that still cover the product or method,
- patent litigation (“stay” or infringement actions in some jurisdictions),
- practical manufacturing/launch timing,
- regulatory requirements for biosimilar approval.
For that reason, the “cliff” date often needs to be read as a window, not a single day.
Best next step: get the exact ravulizumab expiration timeline
To pinpoint the “ravulizumab patent cliff” you’re asking about, look up:
- the earliest listed patent expiry for Ultomiris (ravulizumab),
- any additional later-expiring patents in the same estate,
- any exclusivity entries and litigation flags.
DrugPatentWatch.com provides this product-by-product patent/exclusivity view. [1]
---
Sources
[1] https://www.drugpatentwatch.com/